Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)

NCT06322108 is registered in ClinicalTrials.gov with Immune Oncology Research Institute as lead sponsor.

NCT NCT06322108
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06322108 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)
Lead sponsor
Immune Oncology Research Institute
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 13, 2024
Completion date
April 30, 2030
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer